Venitius Nunez, MD
Psychiatry · Camden, NJNPI 1407973035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 1,134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,134 payments — averaging $13.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$2K
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $5K from 15 others
What the payments were for
- Food & beverage$14,90995%
- Education$7555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 150 | $2,447 |
| Alkermes, Inc. | 131 | $1,963 |
| AbbVie(2 entities) | 153 | $1,760 |
| Sunovion Pharmaceuticals Inc. | 147 | $1,703 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 118 | $1,614 |
| Otsuka America Pharmaceutical, Inc. | 97 | $1,470 |
| Neurocrine Biosciences, Inc. | 81 | $1,002 |
| Vanda Pharmaceuticals Inc. | 67 | $968 |
| Johnson & Johnson | 60 | $955 |
| Lundbeck LLC | 45 | $534 |
| E.r. Squibb & Sons, L.L.C. | 26 | $365 |
| Noven Therapeutics, LLC | 19 | $245 |
| Indivior Inc. | 11 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $149 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $99 |
| Axsome Therapeutics, Inc. | 5 | $73 |
| Almatica Pharma LLC | 5 | $66 |
| Brainsway USA Inc | 1 | $33 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
| Noven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$15,664 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 562 | $884,157 |
| IngrezzaValbenazine Tosylate | 46 | $405,681 |
| VraylarCariprazine Hcl | 264 | $395,947 |
| AustedoDeutetrabenazine | 57 | $365,674 |
| AristadaAripiprazole Lauroxil | 99 | $311,376 |
| Invega SustennaPaliperidone Palmitate | 105 | $263,256 |
| TrintellixVortioxetine Hydrobromide | 352 | $182,428 |
| CaplytaLumateperone Tosylate | 85 | $145,367 |
| FanaptIloperidone | 45 | $112,925 |
| LybalviOlanzapine/Samidorphan Malate | 60 | $99,253 |
| Invega TrinzaPaliperidone Palmitate | 11 | $66,552 |
| Lurasidone Hcl | 177 | $46,295 |
| UzedyRisperidone | 14 | $38,658 |
| Abilify MaintenaAripiprazole | 13 | $36,483 |
| Doxepin Hcl | 376 | $18,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,470 | $920,640575 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,963 | $410,628159 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,002 | $405,68146 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $2,447 | $404,33171 claims |
| AbbVieVraylar | $1,760 | $395,947264 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $955 | $329,808116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $149 | $182,428352 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,614 | $145,36785 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $968 | $112,92545 claims |
| Axsome Therapeutics, Inc.Auvelity | $73 | $15,07413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Camden
- Anthony RostainCamden$110K
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.